Kim Seung Young
Korean J Helicobacter Up Gastrointest Res. 2023 Dec;23(4):240-246. doi: 10.7704/kjhugr.2023.0057. Epub 2023 Dec 8.
Obesity is a global health concern associated with a wide range of diseases, including diabetes, metabolic syndrome, fatty liver, and cardiovascular conditions. Recent studies highlight the significant role of gut microbiota in obesity. Research indicates notable changes in the composition and diversity of gut microbiota in individuals diagnosed with obesity. The gut microbiota participate in energy metabolism, lipid synthesis, and regulation of inflammation and therefore play a key role in the pathogenesis of obesity. Therapeutic approaches based on the use of probiotics, prebiotics, Akkermansia muciniphila, and fecal microbiota transplantation have shown promise in animal studies as useful strategies against obesity and metabolic syndrome. However, further research is warranted to conclusively establish the specific strains, dosages, and mechanisms underlying the effectiveness of these novel strategies against obesity in humans.
肥胖是一个全球健康问题,与多种疾病相关,包括糖尿病、代谢综合征、脂肪肝和心血管疾病。最近的研究强调了肠道微生物群在肥胖中的重要作用。研究表明,被诊断为肥胖的个体肠道微生物群的组成和多样性有显著变化。肠道微生物群参与能量代谢、脂质合成以及炎症调节,因此在肥胖的发病机制中起关键作用。基于使用益生菌、益生元、嗜黏蛋白阿克曼氏菌和粪便微生物群移植的治疗方法在动物研究中显示出有望成为对抗肥胖和代谢综合征的有效策略。然而,需要进一步研究以最终确定这些新型策略对人类肥胖有效性的具体菌株、剂量和机制。